Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Biosynexus

Status and phase: Completed; Phase 3; Phase 2

Conditions: Staphylococcal Sepsis

Treatments: Drug: Placebo; Drug: Pagibaximab 50 mg/mL

Study type: Interventional

Funder types: Industry

Identifiers

NCT00646399

MAB-N007

Details and patient eligibility

About

Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study days 0, 1, 2, 9, 16, and 23.

Full description

Phase 2b/3, randomized, double-blind, multicenter, placebo-controlled study evaluating the safety, efficacy and pharmacokinetics (PK) of pagibaximab (100 mg/kg/dose) in comparison to placebo for the prevention of staphylococcal sepsis in VLBW infants (600 -1200 grams). Subjects monitored for treatment related adverse events and tolerability to infusion of study drug. Neonatal sepsis will be assessed in the presence of clinical signs and symptoms and one blood culture positive for S. aureus or two blood cultures positive for Coagulase Negative Staphylococci (CoNS). The study period will be 35 days after the first dose or until, death, discharge, or transfer, whichever occurs first.

Enrollment: 1,579 patients

Sex: All

Ages: Under 48 hours old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. In-patient at a Neonatal Intensive Care Unit (NICU)
2. Informed consent obtained from the legally authorized representative
3. Less than 48 hours old at the time of first infusion
4. Birth weight between 600 grams and 1200 grams
5. Estimated gestation age ≤33 weeks

For multiple gestations, twins may be enrolled if they each meet the entry criteria. They will both be assigned to the same treatment group.

Exclusion criteria

1. Infants with history of a hypersensitivity or severe vasomotor reaction to any antibody preparation.
2. Infants with proven staphylococcal infection prior to randomization.
3. Infants with a concomitant infection or other medical condition, whose participation, in the opinion of the Investigator and/or medical advisor, may create an unacceptable additional risk.
4. Immunodeficiency other than due to prematurity.
5. Currently receiving, recently received, or planned to receive other investigational agents that could interfere with conduct or results of this study.
6. Severe congenital or chromosomal anomaly that would limit life expectancy or required corrective measures during the period of this study
7. Uncontrolled seizures

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,579 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Phosphate Buffered Saline

Treatment:

Drug: Placebo

Pagibaximab 50 mg/mL

Experimental group

Description:

Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.

Treatment:

Drug: Pagibaximab 50 mg/mL